Navigation Links
Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Date:5/9/2008

SAN DIEGO, May 9 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA), a company focused on the discovery and development of small- molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout, today announced that John W. Beck has been appointed Senior Vice President, Finance and Operations and Chief Financial Officer effective May 27, 2008. He will resign from our board of directors shortly thereafter. The Company also reported recent accomplishments and financial results for the first quarter ended March 31, 2008.

Appointment of John W. Beck as Chief Financial Officer

"We are extremely pleased to welcome John Beck as the new Chief Financial Officer of Ardea," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "John has served as a member of our board of directors since June 2007. He is a proven leader with more than 20 years of financial management experience. We believe that he will play an important role in our ongoing success."

Mr. Beck joins Ardea Biosciences from Metabasis Therapeutics, Inc., which he co-founded in 1999 and where he served most recently as Senior Vice President of Finance, Chief Financial Officer and Treasurer. Prior to Metabasis, he served as Director of Finance of Neurocrine Biosciences, Inc., where he played an important role in Neurocrine's 1996 initial public offering. Prior to joining Neurocrine, Mr. Beck held financial management positions at various high technology and financial services companies, including General Dynamics and Ernst and Young LLP. Mr. Beck received a B.A. in accounting from the University of Washington and also holds a Th.B. in theology from a Seattle, Washington-based seminary. Mr. Beck is a licensed (i
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
11. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2008)... III Study Shows Positive Results with X-ray ...May 9 /- Roche today announced one-ye...wing that ACTEMRA(TM),(tocilizumab) can significan...ints in patients with rheumatoid arthritis (RA), a...ent. The study also demonstrated that ACTEMRA,redu...
(Date:5/8/2008)...ire-FirstCall/ -- DATATRAK International, Inc.,(Na...ocused on global,eClinical solutions for the clini...results for the first quarter of 2008., For the t...d,approximately 41% to $2,088,000 and the Company ...r share on both a basic and diluted basis. These,r...
(Date:5/8/2008).../ -- The Cancer Research Alliance, an,organization...s, is asking,303 million Americans to exercise the...arch efforts this Mother,s Day through Father,s Da...ne(TM)" has two key goals:,to activate Americans e...joining together to exercise their collective powe...
(Date:5/8/2008)...ort potential of asenapine in the treatment of ..., WASHINGTON, May 8 /- Sch...nced that an overview of asenapine clinical trials...st Annual Meeting of the,American Psychiatric Asso...e studies, involving patients with bipolar I disor...
Breaking Medicine Technology:New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 2New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 3New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 5DATATRAK International Reports First Quarter Results for 2008 2DATATRAK International Reports First Quarter Results for 2008 3DATATRAK International Reports First Quarter Results for 2008 4DATATRAK International Reports First Quarter Results for 2008 5DATATRAK International Reports First Quarter Results for 2008 6DATATRAK International Reports First Quarter Results for 2008 7World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 2World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 3World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 4World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 2Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 3Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 4Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 6Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 7Five Hospitals to Share Patient Data 3A ICW Connects Regional Medical Centers and University Facility 6914 1Five Hospitals to Share Patient Data 3A ICW Connects Regional Medical Centers and University Facility 6914 2Five Hospitals to Share Patient Data 3A ICW Connects Regional Medical Centers and University Facility 6914 3TriWest Sponsors Lt Dan Band Performance for Families of Fallen Service Members at Snowball Express Gala 6910 1TriWest Sponsors Lt Dan Band Performance for Families of Fallen Service Members at Snowball Express Gala 6910 2CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference 1947 1CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference 1947 2CSL Behring Reaches Primary Endpoint in Clinical Study of C1 INH for Treatment of Hereditary Angioedema 914 1CSL Behring Reaches Primary Endpoint in Clinical Study of C1 INH for Treatment of Hereditary Angioedema 914 2CSL Behring Reaches Primary Endpoint in Clinical Study of C1 INH for Treatment of Hereditary Angioedema 914 3CSL Behring Reaches Primary Endpoint in Clinical Study of C1 INH for Treatment of Hereditary Angioedema 914 4
(Date:5/12/2008)...2 /PRNewswire-FirstCall/ - The Westaim Corporation...March 31, 2008, it,recorded a net loss of $6.9 mil...lion. In the same quarter last year, the company r... share, on revenues of $6.1 million., Income from...arter,compared to $1.9 million in the same period ...
(Date:5/12/2008)...., May 12 /PRNewswire-FirstCall/ -- (Nasdaq: WHRT,...r the "Corporation") announced,that the Toronto St...ing it,is reviewing the eligibility for continued ...art under sections 709 and 710(a) of the TSX Compa...nancial condition and,operating results, more spec...
(Date:5/12/2008)... 12 /PRNewswire-FirstCall/ -- Allied Healthcare Pr...its net income for the third,quarter ending March ... or,4 cents per share, to about $100,000 in the cu...e third quarter increased by about $240,000 compar..., higher material and labor costs,this fiscal year...
(Date:5/12/2008)... May 12 /Xinhua-PRNewswire-FirstCall/ -- China Yin...) ("China Yingxia" or "the,Company"), a leading pr...e,development, manufacture and distribution of org...ersonal care products in the People,s Republic,of ...onference call,Friday, May 16, 2008, at 10:00 a.m...
Breaking Medicine News(10 mins):Health News:Westaim announces 2008 first quarter results 2Health News:Westaim announces 2008 first quarter results 3Health News:WorldHeart Notified of TSX Delisting Review 2Health News:Allied Healthcare Net Falls on Manufacturing Delays 2Health News:Allied Healthcare Net Falls on Manufacturing Delays 3Health News:Allied Healthcare Net Falls on Manufacturing Delays 4Health News:Allied Healthcare Net Falls on Manufacturing Delays 5Health News:China Yingxia International, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2
...rchers have found that combining pre-operative che...e of survival by six percent when compared with su...rane Researchers from the MRC Clinical Trials Unit...tified 12 eligible randomised controlled trials. ...
...between potential benefits and potential harms whe...etes has to be assessed . This Cochrane Systemati...d a total of 8432 people and found no evidence tha...better patient outcomes when compared with other t...
...r after President Bush unveiled a plan for coping ...nt still has limited capacity to detect a disease...y. The government has also decided that it will no...u outbreak occurs somewhere in the world. Says Dr....
...he first six-month phase of a calorie-restriction ...tion Research Center on Aging (USDA HNRCA) at Tuf...and keeping them in check may be an important comp...ental results from the Comprehensive Assessment of...
Other Medicine News:Health News:Chemotherapy Better for Non Small Cell Lung cancer 2Health News:Americas Preparations For Flu Outbreak Still Incomplete 2Health News:Food Cravings are Linked to Weight Managenemt 2Health News:Food Cravings are Linked to Weight Managenemt 3
MIS Tibial Stylus
Ascent™ Anterior Referencing Femoral Instrument Case
The Lineage acetabular system with ceramic liners uses sophisticated manufacturing methods and materials to minimize wear debris generation.
Link All-Poly acetabular cups for cement.
Medicine Products: